Goldberg Segalla added partner Michael A. Siem to the firm’s Intellectual Property Practice Group in New York City.
Michael is a nationally renowned intellectual property litigator, focusing his practice on complex and high-value patent litigation. He represents both patentees and alleged infringers, appearing regularly before various federal district courts and litigating cases involving many areas of emerging technology, including pharmaceuticals, consumer electronics, chemical processes, computer networks, and biotechnology.
Michael devotes a significant portion of his practice to advising and representing clients in the pharmaceutical industry in litigation within the framework of the Drug Price Competition and Patent Term Restoration Act, or Hatch-Waxman Act. He currently serves as lead trial counsel in several ongoing matters pertaining to Accelerated New Drug Applications (ANDAs), representing some of the largest pharmaceutical manufacturers in the world. Michael’s experience in intellectual property and patent litigation extends far beyond the pharmaceutical and technology industries: He has handled trademark litigation under the Anticybersquatting Consumer Protection Act, and has significant experience in drafting and filing patent and trademark applications across a wide variety of industries.
In recognition of his outstanding pro bono efforts, in 2008 the Committee on Capital Punishment of the Association of the Bar of the City of New York honored Siem with the Thurgood Marshall Award for Capital Representation. In 2012, the American Bar Association presented Siem with the Death Penalty Representation Project Exceptional Service Award.
A graduate of University of Michigan Law School, Michael served as associate editor of the Michigan Telecommunications and Technology Law Review. Before pursuing his law degree, he earned a B.S. in chemical engineering from Illinois Institute of Technology.
Source: www.goldbergsegalla.com
